Putting nature back into medicine.

Evithé biotechnology is expanding the global medicines toolbox by harnessing millions of years of plant evolution into novel botanical drugs with the intention to cure, mitigate, treat or prevent disease in humans.

The unique biodiversity of the South Pacific provides an outstanding opportunity for high value botanical drug development.

Our surveys identified a significant market pull with 78% of consumers indicating to prefer a botanical drug over a synthetic chemical, and 70% of practitioners are confident in prescribing botanical drugs.


Our botanical drug development process is set out to support people with auto-inflammatory diseases. Auto-inflammation is a disease process where the bodies immune system tries to fight an infection, panics and accidentally self-destructs, causing tissue and organ damage.

Auto-inflammation affects 4% of the world population in a variety of degrees of severity from sepsis, to diseases like rheumatoid arthritis to bladder pain, which is known as interstitial cystitis.

The drugs currently used to tackle auto-inflammation are not very effective, and typically tackling just one step in the body’s reaction.

Evithé Biotechnology collaborates with nature

Plants have evolved to produce an array of active constituents to treat diseases by addressing multiple targets at the same time.

Evithé Biotechnology applies nature's evolutionary processes in botanical drug development for better treatment outcomes.

Evithé Biotechnology was founded in 2017. Following an academic journey of 12 years in the field of plant medicine, clinical research and a Masters in Innovation & Commercialisation. 

Evithé biotechnology is inspired by the way that plants have evolved over thousands of years and has found a way to harness their actions into novel botanical drugs with the intention to cure, mitigate, treat or prevent disease in humans.

The Botanical Drug Development Project won multiple awards including:

Watch Evithé's founder Cynthia Hunefeld explain the story behind Evithé (previously HerbScience) for the KiwiNet Awards.

The team

Cynthia Hunefeld

Founder & CEO

Mrs Hunefeld dedicated her life, work and studies in ethnobotany, plant medicine, Post graduate Diploma in clinical research and Masters in Innovation & Commercialisation to the development of botanical medicines.

Dr Andrew Kelly

Executive Chair

Dr Kelly brings his extensive experience in all aspects of the Innovation & Commercialisation through his long and successful career in Australia & New Zealand and his firm BioPacific Partners.

Phil Rasmussen

Chief Science Officer

Honorary Senior Lecturer in Pharmacy at Auckland University with a deep understanding of botanical medicine and product development. Phil founded Phyomed & KiwiHerb and developed them into successful companies that distribute quality controlled botanical medicines all over the world.

Dr Jane Calvert

Legal Advisor

Registered Trans-Tasman patent attorney with a PhD in Organic Chemistry. Jane has unique knowledge of both biotechnology and botanical drug development as well as the requirements for innovation and commercialisation pathways. She brings a wealth of practical experience in building a companies intellectual property portfolio from start-up to large corporate from laboratory to public listing.

Contact us

At our current stage we welcome interest from investors, as well as those that have a desire to follow our developments.

You can also connect with Evithé through our digital channels in order to stay up to date.

Evithé, life is in our name.

Evithé [eɪ Viː teɪ]

An early European derivative of the Hebrew Evia, meaning 'source (or breath) of life'.

©2022 Evithé Biotechnology